Editorial Board About Us

Bob Djavan

All articles from this author are listed below.

Volume 11, Number 3 Review Articles

Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials

Management Update

Elisabeth Eckersberger Julia Finkelstein Helen Sadri Markus Margreiter Herbert Lepor Samir S Taneja Bob Djavan

The advent of prostate-specific antigen (PSA) testing in the early 1980srevolutionized the diagnosis of prostate cancer. As a result of PSA testing,there has been a surge in the number of prostate cancer diagnoses. Thisreview examines the results of 2 recent landmark trials that studied the effectof screening on prostate cancer mortality: the European Randomized Study ofScreening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung,Colorectal, and Ovarian (PLCO) Cancer Screening Trial.[Rev Urol. 2009;11(3):127-133 doi: 10.3909/riu0474]

PSA screening European Randomized Study of Screening for Prostate Cancer(ERSPC)Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Volume 11, Number 3 Meeting Reviews

New Findings in Prostate Cancer

Bob Djavan Franklin E Kuehhas

Highlights From the 24th Annual Congress of the European Association of Urology,March 17–21, 2009, Stockholm, Sweden[Rev Urol. 2009;11(3):169-172 doi:10.3909/riu0455]

Prostate cancer Erectile dysfunction Urinary incontinence Pelvic lymph node dissection Staging European Randomized Study of Screening for Prostate Cancer (ERSPC)

Volume 12, Number 3 Meeting Reviews

Uro-Oncological Controversies in Euro-Oncology

Meeting Review

Alexander Farr Elisabeth Eckersberger Helen Sadri Markus Margreiter Mike Harik Herbert Lepor Bob Djavan

Highlights From the European Association of Urology Section of Oncological Urology, January 15-17, 2010, Vienna, Austria [Rev Urol. 2010;12(2/3):e125-e128 doi: 10.3909/riu0491]

Prostate cancer screening Bladder cancer Renal cancer Robotics Cancer mortality rates

Volume 12, Number 3 Meeting Reviews

Oncological Update: New Findings in Bladder and Prostate Cancer

Meeting Review

Roman Herout Alexander Farr Markus Margreiter Bob Djavan Franklin E Kuehhas

Highlights From the 25th Anniversary Congress of the European Association of Urology, April 16-20, 2010, Barcelona, Spain [Rev Urol. 2010;12(2/3):e129-e133 doi: 10.3909/riu0499]

Prostate cancer Androgen deprivation therapy Bladder cancer Radical prostatectomy Radical cystectomy Carcinoma in situ Anastomotic stricture

Volume 12, Number 1 Review Articles

Open Versus Laparoscopic Versus Robot-Assisted Laparoscopic Prostatectomy: The European and US Experience

Treatment Update

Julia Finkelstein Elisabeth Eckersberger Helen Sadri Samir S Taneja Herbert Lepor Bob Djavan

Open radical prostatectomy (ORP) is the reference standard for the surgical management of localized prostate cancer. With wider availability of minimally invasive radical prostatectomy techniques, there is a debate regarding the standard treatment of the management of localized prostate cancer. Therefore, we reviewed the current status of laparoscopic radical prostatectomy (LRP) and robotic-assisted laparoscopic radical prostatectomy (RALRP) as compared with ORP. Because no prospective, randomized trials comparing the different techniques have been performed, outcomes must be assessed from published series by centers that focus on ORP, LRP, and RALRP. Aside from reducing the amount of blood loss, current data suggest that the most significant outcomes (cure, continence, and potency) are no better with LRP or RALRP than with conventional ORP. Therefore, in experienced hands, ORP remains the gold standard procedure. However, there is a trend toward consistently better outcomes following RALRP in comparison with LRP. In the end, individual patient outcomes can be maximized by choosing the best modality based on the patient’s comorbid medical conditions, cancer characteristics, and surgeon experience. Future studies are needed to further investigate long-term cancer control as well as functional outcomes for RALRP series.[Rev Urol. 2010;12(1):35-43 doi: 10.3909/riu0470]

Prostatic neoplasms Laparoscopy Prostatectomy Robotics

Volume 13, Number 2 Meeting Reviews

New Findings in Benign Prostatic Hyperplasia and Incontinence

Highlights From the 26th Annual Congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria

Alexander Farr Sabina Sevcenco Roman Herout Bob Djavan Amir Kazzazi

[Rev Urol. 2011;13(2):112-117 doi: 10.3909/riu0526]

Benign prostatic hyperplasia Nocturia Incontinence

Volume 15, Number 1 Review Articles

Laser Prostatectomy: Holmium Laser Enucleation and Photoselective Laser Vaporization of the Prostate

Treatment Update

Yakup Bostanci Amir Kazzazi Bob Djavan

Historically, transurethral resection of the prostate has been the gold standard for the treatment of benign prostatic hyperplasia (BPH). Laser technology has been used to treat BPH for ? 15 years. Over the past decade, it has gained wide acceptance by experienced urologists. This review provides an evidence-based update on laser surgery for BPH with a focus on photoselective laser vaporization and holmium laser enucleation of the prostate surgeries and assesses the safety, efficacy, and durability of these techniques. [Rev Urol. 2013;15(1):1-10 doi: 10.3909/riu0553] © 2013 MedReviews®, LLC

Benign prostatic hyperplasia Laser prostatectomy Lithium triborate laser Potassium-titanyl-phosphate laser